Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company reports a corporate governance event dated September 13, 2017. The filing details the election of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change is the expansion of the Board of Directors. The Board size will increase to eleven members effective January 1, 2018, following the election of Karen H. Vousden, Ph.D.
Management Commentary and Compensation
Dr. Vousden, currently Group Leader at the Francis Crick Institute and Chief Scientist at Cancer Research UK, was determined to be independent under NYSE Listing Standards. She will serve on the Science and Technology Committee. Her compensation package includes:
- Annual retainer: $100,000
- Annual award of deferred share units: $170,000 (valued on grant date)
- Science and Technology Committee retainer: $15,000
There are no related party transactions or special arrangements associated with this election.
Investor Verification Checklist
- Confirm the effective date of Dr. Vousden's board membership (January 1, 2018).
- Verify the total number of board seats following the expansion to eleven.
- Review the attached press release (Exhibit 99.1) for additional biographical details.
- Note that this filing contains no financial results or guidance updates.